Shiga toxin (Stx) is the main virulence factor of enterohemorrhagic Escherichia coli (eHec), that cause gastrointestinal infection leading to hemolytic uremic syndrome. The aim of this study was to investigate if Stx signals via ATP and if blockade of purinergic receptors could be protective. Stx induced ATP release from HeLa cells and in a mouse model. Toxin induced rapid calcium influx into HeLa cells, as well as platelets, and a P2X1 receptor antagonist, NF449, abolished this effect. Likewise, the P2X antagonist suramin blocked calcium influx in Hela cells. NF449 did not affect toxin intracellular retrograde transport, however, cells pre-treated with NF449 exhibited significantly higher viability after exposure to Stx for 24 hours, compared to untreated cells. NF449 protected HeLa cells from protein synthesis inhibition and from Stx-induced apoptosis, assayed by caspase 3/7 activity. The latter effect was confirmed by P2X1 receptor silencing. Stx induced the release of toxin-positive HeLa cell-and platelet-derived microvesicles, detected by flow cytometry, an effect significantly reduced by NF449 or suramin. Suramin decreased microvesicle levels in mice injected with Stx or inoculated with Stx-producing EHEC. Taken together, we describe a novel mechanism of Stx-mediated cellular injury associated with ATP signaling and inhibited by P2X receptor blockade.
P2X1 receptor antagonist inhibited Stx1 and Stx2-induced calcium influx.
To evaluate the importance of Stx-induced ATP-release for Stx1-mediated signaling, experiments were carried out to study if the P2X1 antagonist NF449, or the non-selective P2X inhibitor suramin, could block calcium influx induced by Stx1. HeLa cells loaded with Fluo-4 calcium indicator dye and stimulated with Stx1 displayed a swift and steady increase in cytosolic calcium, lasting for the duration of the experiment, 270 sec ( Fig. 2A) . NF449-and suramin-pretreated cells exhibited significantly less calcium influx after Stx1 stimulation compared to untreated cells, remaining at stable low calcium concentration levels throughout the experiment ( Fig. 2A) as did the HBSS negative control. As a positive control, NF449 treated and untreated HeLa cells were stimulated with ATP. ATP induced a clear calcium response in HeLa cells, while NF449 treated cells were unaffected ( Supplementary Fig. S2 ). were stimulated with Shiga toxin 1 (Stx1) or PBS and the ATP content was measured after 5 min. The median extracellular ATP content is depicted as the bars. (B) HeLa cells were stimulated with Stx1 (n = 12), A23187 calcium ionophore (n = 8) or PBS (n = 11). The supernatant was collected and free phosphate groups were measured. Data is depicted as median absorbance at OD 600 (denoted by the bars), correlating to free phosphate groups in the supernatant. (C) Mice were injected with Stx2 at a concentration of 285 (n = 4), 142.5 (n = 7) or 71.25 ng/kg (n = 3) or with PBS as the control. Mice injected with Stx2 142.5 ng/kg had significantly higher plasma ATP levels compared to PBS control mice. A similar trend was seen for mice injected with Stx2 285 ng/kg, although the difference did not achieve statistical significance. Mice injected with Stx2 71.25 ng/kg had plasma ATP levels comparable to PBS control mice. The median is denoted by the bar. *P < 0.05, ****P < 0.0001, two-tailed Mann-Whitney test (panel A) and Kruskal-Wallis test (panels B and C).
A similar experiment was carried out using human platelets stimulated with Stx1 or Stx2, together with E. coli O157 lipopolysaccharide (LPS) to stimulate platelet activation 18, 30 . An increase in intracellular calcium levels was noted upon Stx1 ( Fig. 2B ) and Stx2 (Fig. 2C) stimulation. When the cells were pre-treated with NF449 calcium influx was not detected (Fig. 2B,2C ). Stx1, Stx2 or O157LPS alone did not have a significant effect on the influx of calcium ( Supplementary Fig. S3A,B ).
Stx1 localization to the ER was not affected by the P2X1 receptor antagonist. The effect of
the P2X1 receptor antagonist NF449 on Stx1-retrograde transport was studied using HeLa cells expressing a SNAP-tag localized to the ER that were incubated with Stx1B labeled with the binding substance O 6 -benzylguanine. NF449 did not affect retrograde trafficking of the toxin to the ER whereas the positive control, the Ca 2+ chelator BAPTA-AM, resulted in significantly less toxin locating to the ER (Fig. 3 ).
P2X1 receptor antagonist protected HeLa cells from the cytotoxic effects of Stx. Stx1-and
Stx2-treated HeLa cells exhibited considerable cell death, a median of 10.8% (range 2.7-21.3%) and 10.1% (range 6.8-25.9%), respectively, were viable after 24 h. Cell viability was significantly higher in cells that were pre-treated with NF449 with a median of 72.3% (range 63.9-97.9%) for Stx1 and 62.4% (34.9-109.6%) for Stx2 compared to PBS-treated cells, defined as 100% viability (Fig. 4A ).
Figure 2.
The effect of purinergic antagonists on calcium influx induced by Shiga toxin in HeLa cells and human platelets. (A) Calcium influx was measured in HeLa cells preincubated with NF449, suramin or phosphate buffered saline (PBS) vehicle, stimulated with Shiga toxin 1 (Stx1) or Hank's balanced salt solution (HBSS) (groups differentiated by icon colors) and imaged by fluorescence microscopy. Results are presented as mean fluorescent change of all cells in the field of view (median and range). The color of the asterisks corresponds to the color of the icon in comparison to Stx1. The absence of asterisks indicates that statistics was not significant. (B-C) Human platelets (n = 3 donors) were preincubated with NF449 or PBS vehicle followed by Stx1 (B) or Stx2 (C) and O157LPS (to enable platelet activation by Shiga toxin) or PBS vehicle. Data is presented as the initial fluorescence subtracted from fluorescence after 2 minutes and the bar denotes the median fluorescence. RFU: relative fluorescent units, ns: not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-way repeated measure ANOVA (panel A) and Kruskal-Wallis test (panels B and C).
P2X1 receptor antagonist partially protected HeLa cells from Stx1-mediated ribotoxicity.
The effect of Stx1 on protein synthesis was investigated in the presence of NF449. HeLa cells incubated with Stx1 alone for 4 h displayed a median of 28% (range 13-49%) protein synthesis compared to unstimulated control cells (defined as 100%). Pre-incubation with NF449 increased protein synthesis to 37% (range 27-56%) compared to unstimulated cells ( Fig. 4B ).
P2X1 receptor antagonist reduced Stx1-induced caspase 3/7 activation. Stx1 was incubated with
HeLa cells for 24 h and induced caspase 3/7 activation in a majority of the cells, suggesting the induction of apoptotic signals ( Fig. 4C ). Pretreatment with NF449 lead to significantly less caspase 3/7 activation per cell ( Fig. 4C ). Similar results were obtained with Stx2 ( Supplementary Fig. S4 ).
Cells with reduced P2X1 receptor expression, due to silencing, displayed significantly lower caspase-3/7 activation in response to Stx1 compared to control cells transfected with a scrambled sequence ( Fig. 4D ), supporting involvement of the receptor. PBS-treated native (n = 3) and P2X1-silenced HeLa cells (n = 2) did not display caspase 3/7-activation (data not shown).
P2X receptor antagonists decreased the release of Stx1 and Stx2-positive microvesicles.
Calcium influx induces microvesicle release 31 and, as shown above, Stx triggers calcium influx, which has also been demonstrated for Stx1B 14 . Stx1B stimulation induced microvesicle release from HeLa cells that was reduced in the presence of NF449, although this did not achieve statistical significance ( Fig. 5A ). HeLa cell-derived microvesicles containing Stx1B were significantly reduced in the presence of NF449 ( Fig. 5B ). Experiments were also carried out in whole blood in which Stx1 (holotoxin) induced a significant release of microvesicles from platelets ( Fig. 5C ) and NF449 significantly reduced the release of Stx1-positive platelet microvesicles ( Fig. 5D ). Similar experiments were carried out with Stx2 (holotoxin). Stx2 stimulation induced the release of HeLa cell microvesicles, an effect that was significantly reduced by NF449 ( Fig. 5E ). Likewise, the release of toxin-positive microvesicles was significantly decreased by NF449 ( Fig. 5F ). Platelet-derived microvesicles were released in whole blood stimulated with Stx2 ( Fig. 5G ), this effect was significantly reduced by suramin ( Supplementary  Fig. S5 ) and by NF449, albeit without achieving significance ( Fig. 5G ). Significantly less Stx2-positive platelet microvesicles were released in the presence of NF449 ( Fig. 5H ).
Suramin inhibits Stx2-induced platelet-derived microvesicle release in vivo in a Stx2 and EHEC mouse model. The effect of suramin treatment on platelet-derived microvesicles, and the release of
Stx2-positive microvesicles, was assessed in BALB/c mice injected with Stx2. Suramin was chosen for the in vivo studies due to its non-selective antagonistic properties with regard to P2X receptors 32 . Levels of platelet-derived microvesicles were significantly higher in mice injected with Stx2 compared to controls ( Fig. 6A ). Platelet-derived microvesicles and those that were Stx2-positive were significantly lower in suramin-treated mice (Fig. 6A,B) .
The effect of suramin treatment was assessed in BALB/c mice infected with Stx2-producing E. coli O157:H7. The number of total platelet-derived microvesicles, and those that were Stx2-positive, in plasma from mice infected with E. coli O157:H7 was significantly higher compared to the control mice (inoculated with vehicle) and suramin treatment significantly reduced this effect ( Fig. 6C,6D) . 
Discussion
Stx, the major virulence factor of EHEC strains, causes massive intestinal and renal cellular damage. This study demonstrates a novel mechanism by which Stx activates and damages cells. Stx induces a cellular signal promoting the release of ATP followed by ATP signaling via purinergic receptors, leading to calcium influx into cells associated with toxin-associated cellular damage and microvesicle release. Stx mediates cellular injury by binding to the Gb3 receptor and undergoing cellular uptake, retrograde transport and thereafter causing cell death by inhibition of protein synthesis and induction of apoptosis. The toxin gains access to the circulation, binds to blood cells and induces the release of blood cell-derived microvesicles 33 . Stx reaches the kidney bound to the cell membrane of blood cells or within blood cell-derived microvesicles 16 . This study shows that ATP signaling is involved in fundamental aspects of Stx-mediated cellular effects as depicted in Fig. 7 . This novel ATP-mediated effect of Stx was inhibited by the P2X1 antagonist NF449, and the non-selective antagonist suramin. NF449 blocked toxin-associated calcium influx and reduced cytotoxicity, associated with inhibited protein synthesis and caspase activity, as well as microvesicle release. The latter effect, on microvesicle release, was confirmed in two in vivo models using Stx2 injection and E. coli O157 inoculation. Purinergic antagonism could thus block crucial aspects of Stx-induced cellular activation and injury. The findings suggest that ATP signaling can promote the cellular effects of Stx and that blocking purinergic receptors may have a protective effect. www.nature.com/scientificreports www.nature.com/scientificreports/ Stx1 induces calcium influx 14 . The mechanism by which the toxin induces calcium influx has not been previously elucidated. Here we show that toxin induces ATP efflux, which then binds to and activates the P2X1 receptor triggering calcium influx that could be demonstrated for both Stx1 and Stx2. The effect of Stx2 was specifically assayed in the presence of apyrase, in order to catalyze the hydrolysis of preformed ATP to ADP and AMP and thereby reduce P2X1 desensitization 34 . This effect of Stx was totally abrogated by the P2X1 receptor antagonist NF449 in HeLa cells (for Stx1) and in platelets (for Stx1 and Stx2). We used HeLa cells throughout the study to obtain reproducible results not dependent on variations between donors and showed that the cells express the P2X1 receptor. We chose to show the effect of Stx1 and Stx2 on ATP signaling even in platelets as these cells are known to express P2X1 35 and signaling via the P2X1 receptor was shown to induce calcium influx in platelets (reviewed in 24 ). Moreover, once Stx gains access to the bloodstream it binds to platelets 18 , thus the signaling induced in platelets, and its abrogation by NF449, may have relevance in the clinical disease setting.
Blocked ATP signaling and calcium influx affected the ultimate cellular effects of Stx1, i.e. the induction of cell death by inhibited protein translation and apoptosis. These effects were reduced in the presence of the P2X1 receptor antagonist NF449. Calcium flux has been implicated in the induction of apoptosis (reviewed in 36 ). Ribosome-inactivating proteins, such as ricin and Stx, of plant or microbial origin, respectively, require intracellular calcium to induce apoptosis 37 . Calcium transfer from the ER to mitochondria induced by Stx1, leading to release of cytochrome c, activation of caspase-9 and production of reactive oxygen species, caused cell death by apoptosis 11, 38 . Moreover, calpain activity, involved in Stx1-mediated caspase-8 cleavage and apoptosis, is calcium-dependent 39 . The ribosome-inactivating RNA N-glycosidase activity of ricin was shown to be divalent cation-dependent 40 . Taken together, the effects of Stx1 on inhibition of protein synthesis and the induction of apoptosis are calcium-dependent, thus NF449 could affect these intracellular pathways by inhibiting calcium influx, thereby exerting a protective effect.
In calcium-free medium Stx1B does not induce calcium influx 14 , indicating that the elevated calcium originates from an extracellular source. NF449 did not affect the transport of the toxin to the ER, while BAPTA-AM (the positive control) did (Fig. 3) . BAPTA-AM is a cell permeable version of BAPTA that can chelate intracellular divalent cations with high specificity for Ca 2+ , leaving minimal levels of free intracellular Ca 2+ , whereas NF449 affects Ca 2+ influx into cells, but not intracellular Ca 2+ sources. As NF449 does not perturb intracellular Ca 2+ sources this may explain why toxin transport to the ER was not affected.
The P2X receptors differ in the number of their subunits, from 1 to 7, and these subunits share a certain degree of homology 41 . NF449 is considered highly selective for the P2X1 receptor even at nanomolar concentrations 32, 42 . Concentrations in the micromolar range, such as used by others 43, 44 and in the current study, have a higher P2X1 antagonist potency, but even a certain effect on other purinergic receptors 32 . P2X1 receptor silencing followed by caspase detection after challenging HeLa cells with Stx1 showed a protective effect similar to NF449 blockade. The effect of ATP blockade on calcium influx in vitro, and microvesicle release in vitro and in vivo, was also confirmed using the non-selective P2X antagonist, suramin, with a varying effect on all P2X receptors 32 .
Stx2 induces the release of microvesicles from blood cells 18 and, as shown here, Stx1 and Stx2 induce the release of microvesicles from HeLa cells and platelets. Microvesicles contain cytosolic content from their parent cell, and, in the case of a toxin-affected cell, the microvesicles will carry toxin and thereby transfer their cargo to a recipient cell 16 . This mechanism of transfer of injurious substances via microvesicles will evade the host response as the toxin will be protected by host membranes. Thus, a substance capable of decreasing microvesicle release could be protective, in conditions in which microvesicles promote disease in general 45, 46 , and in Stx-mediated disease in particular. NF449 inhibited Stx-induced microvesicle release from HeLa cells and platelets, and suramin reduced microvesicle release from platelets, both in vitro and in vivo. Calcium influx is required for microvesicle www.nature.com/scientificreports www.nature.com/scientificreports/ shedding 47 and thus the decreased microvesicle release in the presence of NF449 and suramin would presumably be associated with blocked calcium influx via the P2X1 receptor 48 .
Suramin is used commercially for the treatment of parasite infections in humans 49 as well as autistic spectrum disorders in mouse models 50 . In a recent study we reported that red blood cells stimulated with Stx2 released microvesicles, an effect modulated by the non-selective P2X receptor inhibitors suramin and PPADS 15 . We propose that the beneficial effects of NF449 and suramin on microvesicle release should be further explored as microvesicles have been associated with the transfer of deleterious substances in various disease states 46 .
We conclude that Stx induces an intracellular signal via ATP interaction with purinergic receptors allowing calcium influx and promoting the injurious effects of the toxin on cell viability, the inhibition of protein synthesis and apoptosis. Furthermore, the ATP-induced signal stimulates microvesicle release from cells. This may be a protective mechanism by which cells rid themselves of toxic substances but may also promote disease, as these microvesicles circulate with toxic content thus reaching the kidney which is the target organ 16 . We demonstrate that purinergic P2X blockade abrogated the injurious effects of Stx related to calcium influx, viability and microvesicle release and therefore suggest purinergic signaling as a novel mechanism of Stx-mediated cellular injury. Purinergic signaling blockade should be explored as a novel therapeutic option in Stx-mediated disease.
Methods

HeLa cells and platelets. HeLa cells were cultured in Dulbecco's Modified Eagle Medium (DMEM,
Invitrogen, Paisley, UK) with supplements and seeded at a density of 10 5 cells/mL 24 hours before the start of experiments, as described in the supplement.
For the isolation of platelet-rich-plasma, blood was drawn from healthy adult donors into Vacutainer tubes (Becton Dickinson, Franklin Lanes, NJ) containing Lepirudin (50 μg/mL, Refludan, Celgene, Windsor, UK), as detailed in the supplement. The study was performed with the approval of the Regional Ethics Review Board of Lund University, the written informed consent of the subjects (healthy adult donors) in accordance with relevant guidelines and regulations.
Detection of the P2X1 receptor on HeLa cells and platelets.
The presence of the P2X1 receptor on HeLa cells and platelets was confirmed by immunoblotting (see description in the supplement) using an anti-P2X1 primary antibody (1 μg/mL, ab74058, Abcam, Cambridge, UK). The observed band corresponded to approximately 60 kDa, which is the receptor size reported for P2X1 35 , shown in Supplementary Fig. S6.   Figure 7 . Proposed mechanism of Shiga toxin induced cellular activation via ATP. Schematic diagram displaying a proposed mechanism by which Shiga toxin induces cellular activation, utilizing ATP as a second messenger. When Shiga toxin binds to its receptor, globotriaosylceramide (Gb3), cells release ATP. ATP in turn binds to P2X receptors causing Ca 2+ -influx into the cell. Ca 2+ is necessary for intracellular processes associated with Shiga toxin induced cell death and the shedding of toxin-positive microvesicles (MVs). Purinergic receptor blockade, such as NF449 and suramin, used in this study, block P2X-activation and these Shiga toxin-mediated effects. Filled arrows show the transport route of Shiga toxin and dashed arrows show ATP-mediated signaling. ER: endoplasmic reticulum. This illustration was created using software from Motifolio.
Isolation and detection of microvesicles from HeLa cells and platelets.
HeLa cells were stimulated with Stx1B:Alexa488 or Stx2. Microvesicles were isolated and labeled with mouse anti-CD44PE and rabbit anti-Stx2 (BEI resources, Manassas, VA) and swine anti-rabbit FITC (Dako, Glostrup, Denmark), both diluted in 0.1% saponin (Sigma-Aldrich). Platelets were stimulated with Stx1 or Stx2. Microvesicles were isolated and labeled with mouse anti-CD42PE and mouse anti-Stx1 (Santa Cruz Biotechnology, Dallas, TX) and goat anti-mouse FITC (Dako), both diluted in 0.1% saponin, or rabbit anti-Stx2 as above. The procedure is detailed in the supplement.
Mice. BALB/c wild-type mice were bred in the animal facilities of the Biomedical Service Division, Medical Faculty, Lund. Both female and male mice were used at 8-13 weeks of age and were age-matched. All animal experiments were approved by the animal ethics committee of Lund University and carried out in accordance with the guidelines of the Swedish National Board of Agriculture and the EU directive for the protection of animals used in science. Approval numbers M13-14 and M148-16.
Shiga toxin 2-injection mouse model. Stx2 was injected intraperitoneally at 285, 142.5 or 71.25 ng/ kg body weight and control mice received PBS, as previously described 27 . Mice were monitored daily. In the Stx2-injection model mice usually show symptoms on day 3. For microvesicle counts mice were sacrificed on day 3 and for ATP assay mice were sacrificed upon showing signs of disease or on day 7. The procedure is detailed in the supplement. Escherichia coli O157:H7-infection mouse model. Mice were infected with E. coli O157:H7 (10 8 CFU/ mouse) as previously described 27, 53 . Mice were sacrificed on day 3 after inoculation, before the development of symptoms. Blood was collected for microvesicle analysis as described above. See the supplement for details.
Treatment of Stx2-injected and EHEC-infected mice with suramin. BALB/c mice were injected
intraperitoneally with suramin and control mice received vehicle 16 hours before injection of Stx2 intraperitoneally or one hour before inoculation with E. coli O157:H7 or its corresponding vehicle. All mice were sacrificed on day 3 post inoculation and samples were collected for microvesicle analysis, as described in the supplement.
Isolation and labeling of murine microvesicles. Microvesicles were isolated and labeled as previously described 16 . Platelet microvesicles were detected with rat anti-mouse CD41:APC (BD Biosciences) and Stx2-containing microvesicles were detected as described above. See the supplement for details.
